Top

Published in:

01-12-2014 | Editorial

Identifying the gaps between science, policies, services, and the needs of youths affected by mental disorders

Author: Guilherme V. Polanczyk

Published in: European Child & Adolescent Psychiatry | Issue 12/2014

Excerpt

Mental disorders are estimated to affect 10–20 % of children and adolescents around the world and are major causes of morbidity among youth [10]. Evidence from different countries suggests that the number of youths with reported diagnoses of mental disorders in the community has increased substantially during the past decades [1, 17], although there is no evidence to indicate that the actual prevalence of disorders has increased [12]. Surprisingly, despite the fact that mental disorders have been increasingly recognized by professionals and the community, associated morbidity and mortality have remained stable [3]. …

Atladottir HO, Gyllenberg D, Langridge A, Sandin S, Hansen SN, Leonard H et al (2014) The increasing prevalence of reported diagnoses of childhood psychiatric disorders: a descriptive multinational comparison. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-014-0553-8 PubMed

Belfer ML (2007) Critical review of world policies for mental healthcare for children and adolescents. Curr Opin Psychiatry 20(4):349–352. doi:10.1097/YCO.0b013e3281bc0cf4 PubMedCrossRef

Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS et al (2011) Grand challenges in global mental health. Nature 475(7354):27–30. doi:10.1038/475027a PubMedCentralPubMedCrossRef

Costello EJ, He J-P, Sampson NA, Kessler RC, Merikangas KR (2014) Services for adolescents with psychiatric disorders: 12-month data from the National Comorbidity Survey–Adolescent. Psychiatric Serv (Washington, DC) 65(3):359. doi:10.1176/appi.ps.201100518 CrossRef

Insel TR (2014) Mental disorders in childhood: shifting the focus from behavioral symptoms to neurodevelopmental trajectories. JAMA 311(17):1727–1728

Merikangas KR, He J-P, Rapoport J, Vitiello B, Olfson M (2013) Medication use in US youth with mental disorders. JAMA Pediatrics 167(2):141. doi:10.1001/jamapediatrics.2013.431 PubMedCrossRef

Nafees B, Setyawan J, Lloyd A, Ali S, Hearn S, Sasane R et al (2014) Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-013-0515-6 PubMed

Olfson M, Blanco C, Liu S-M, Wang S, Correll CU (2012) National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 69(12):1247–1256. doi:10.1001/archgenpsychiatry.2012.647 PubMedCrossRef

Olfson M, Crystal S, Huang C, Gerhard T (2010) Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 49(1):13–23. doi:10.1016/j.jaac.2009.09.003 PubMed

10.

Patel V, Flisher AJ, Hetrick S, McGorry P (2007) Mental health of young people: a global public-health challenge. Lancet 369(9569):1302–1313. doi:10.1016/S0140-6736(07)60368-7 PubMedCrossRef

11.

Patel V, Kieling C, Maulik PK, Divan G (2013) Improving access to care for children with mental disorders: a global perspective. Arch Dis Child 98(5):323–327. doi:10.1136/archdischild-2012-302079 PubMedCentralPubMedCrossRef

12.

Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA (2014) ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. doi:10.1093/ije/dyt261 PubMed

13.

Pottegård A, Zoëga H, Hallas J, Damkier P (2014) Use of SSRIs among Danish children: a nationwide study. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-014-0523-1 PubMed

14.

Pringsheim T, Lam D, Patten SB (2011) The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005–2009. J Child Adolesc Psychopharmacol 21(6):537–543. doi:10.1089/cap.2010.0145 PubMedCrossRef

15.

Tarver J, Daley D, Lockwood J, Sayal K (2014) Are self-directed parenting interventions sufficient for externalising behaviour problems in childhood? A systematic review and meta-analysis. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-014-0556-5

16.

The PERS Consortium, Glennon J, Purper-Ouakil D, Bakker M, Zuddas A, Hoekstra P et al (2013) Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-013-0498-3

17.

Visser SN, Danielson M, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM et al (2013) Trends in the parent––report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. J Am Acad Child Adolesc Psychiatry 53(1):34–46.e2. doi:10.1016/j.jaac.2013.09.001 PubMedCrossRef

Title: Identifying the gaps between science, policies, services, and the needs of youths affected by mental disorders
Author: Guilherme V. Polanczyk
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: European Child & Adolescent Psychiatry / Issue 12/2014
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-014-0650-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Identifying the gaps between science, policies, services, and the needs of youths affected by mental disorders

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2014

Atomoxetine-induced wake-time teeth clenching and sleep bruxism in a child patient

The association between depressive symptoms from early to late adolescence and later use and harmful use of alcohol

Atomoxetine-induced mydriasis in a child patient

Life-course fertility patterns associated with childhood externalizing and internalizing behaviors

Are self-directed parenting interventions sufficient for externalising behaviour problems in childhood? A systematic review and meta-analysis

Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges